Experienced in Pancreatectomy

Dr. Theodore S. Hong

Radiation Oncology
The General Hospital Corporation
2014 Washington St, 
Newton, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Pancreatectomy
The General Hospital Corporation
2014 Washington St, 
Newton, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Theodore Hong is a Radiation Oncologist in Newton, Massachusetts. Dr. Hong is rated as an Experienced provider by MediFind in Pancreatectomy. His top areas of expertise are Pancreatic Cancer, Anal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreaticoduodenectomy, and Tissue Biopsy. Dr. Hong is currently accepting new patients.

His clinical research consists of co-authoring 289 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles in the study of Pancreatectomy.

Specialties
Radiation Oncology
Licenses
Radiology in MA
Hospital Affiliations
Newton-Wellesley Hospital
Massachusetts General Hospital
Emerson Hospital -
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

THE GENERAL HOSPITAL CORPORATION
2014 Washington St, Newton, MA 02462
Other Locations
MASSACHUSETTS GENERAL PHYSICIANS ORGANIZATION INC
55 Fruit St, Boston, MA 02114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma
A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma
Enrollment Status: Recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Procedure, Radiation
Study Phase: Phase 3
A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: FOLFIRINOX, Losartan, Nivolumab
Study Phase: Phase 2
Phase II Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases
Phase II Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases
Enrollment Status: Completed
Publish Date: September 30, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
Phase II Study of Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma
Phase II Study of Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
A Pilot Feasibility Study of Definitive Concurrent Chemoradiation With Pencil Beam Scanning Proton Beam in Combination With 5-Fluorouracil and Mitomycin-C for Carcinoma of the Anal Canal
A Pilot Feasibility Study of Definitive Concurrent Chemoradiation With Pencil Beam Scanning Proton Beam in Combination With 5-Fluorouracil and Mitomycin-C for Carcinoma of the Anal Canal
Enrollment Status: Completed
Publish Date: September 05, 2025
Intervention Type: Drug, Radiation
Study Drugs: 5-fluorouracil, Mitomycin-C
Study Phase: Early Phase 1
Phase Ib/II Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
Phase Ib/II Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 22, 2025
Intervention Type: Radiation, Drug
Study Drug: TAS-102
Study Phase: Phase 1/Phase 2
A Phase II Study of Niraparib and Dostarlimab With Radiation in Patients With Metastatic Pancreatic Cancer
A Phase II Study of Niraparib and Dostarlimab With Radiation in Patients With Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Radiation
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 2
Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable (MSS) and Microsatellite Instability (MSI) High Colorectal and Pancreatic Cancer
Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable (MSS) and Microsatellite Instability (MSI) High Colorectal and Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery
Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery
Enrollment Status: Active_not_recruiting
Publish Date: May 29, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: Carboplatin, Paclitaxel, Telomerase-specific Type 5 Adenovirus OBP-301
Study Phase: Phase 1
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
Enrollment Status: Unknown
Publish Date: October 05, 2022
Intervention Type: Drug, Radiation
Study Phase: Phase 1
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Pancreatic Cancer
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2022
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Colorectal Cancer
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Colorectal Cancer
Enrollment Status: Unknown
Publish Date: September 08, 2022
Intervention Type: Drug, Radiation
Study Phase: Phase 2
An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer
An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer
Enrollment Status: Completed
Publish Date: October 04, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 1
Phase II Study of Preoperative FOLFIRINOX Followed by Accelerated Short Course Radiation Therapy for Borderline-Resectable Pancreatic Cancer
Phase II Study of Preoperative FOLFIRINOX Followed by Accelerated Short Course Radiation Therapy for Borderline-Resectable Pancreatic Cancer
Enrollment Status: Unknown
Publish Date: May 28, 2021
Intervention Type: Procedure, Radiation, Drug
Study Drugs: FOLFIRINOX, Capecitabine
Study Phase: Phase 2
Phase II Feasibility Study of FOLFIRINOX-Losartan Followed by Accelerated Short Course Radiation Therapy With Capecitabine for Locally Advanced Pancreatic Cancer
Phase II Feasibility Study of FOLFIRINOX-Losartan Followed by Accelerated Short Course Radiation Therapy With Capecitabine for Locally Advanced Pancreatic Cancer
Enrollment Status: Unknown
Publish Date: September 25, 2020
Intervention Type: Drug, Radiation
Study Drugs: FOLFIRINOX, Losartan
Study Phase: Phase 2
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: August 28, 2019
Intervention Type: Radiation
Study Phase: Phase 3
A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer
A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer
Enrollment Status: Withdrawn
Publish Date: July 08, 2019
Intervention Type: Other
Phase I Study of Chemoradiation With Midostaurin (PKC412) For Locally Advanced Rectal Cancer
Phase I Study of Chemoradiation With Midostaurin (PKC412) For Locally Advanced Rectal Cancer
Enrollment Status: Completed
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 17 Less Clinical Trials

288 Total Publications

Challenges Remaining for Yttrium-90 Radioembolization: The Case for Standardized Dosimetry and Comparative Local Control Analyses in Liver Tumors.
Challenges Remaining for Yttrium-90 Radioembolization: The Case for Standardized Dosimetry and Comparative Local Control Analyses in Liver Tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 14, 2025
Similar Doctors
Experienced in Pancreatectomy
Dr. Jennifer Y. Wo
Radiation Oncology
Experienced in Pancreatectomy
Dr. Jennifer Y. Wo
Radiation Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (9.4 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jennifer Wo is a Radiation Oncologist in Boston, Massachusetts. Dr. Wo is rated as a Distinguished provider by MediFind in Pancreatectomy. Her top areas of expertise are Pancreatic Cancer, Anal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreaticoduodenectomy, and Tissue Biopsy. Dr. Wo is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hong's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 10 Advanced Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile